Patents by Inventor Lisa Davidson

Lisa Davidson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230091992
    Abstract: An alignment system that monitors posture and provides alignment feedback about the monitored posture to an individual is described. This alignment system may include an alignment device that is worn or remateably attached to the body of the individual, e.g., in or near a midline (such as at or near a midpoint between the Iliac Fossa) of the posterior lumbar or sacral region. The alignment device may include one or more alignment sensors and/or may communicate with one or more separate alignment sensors that monitor the alignment of the individual's pelvis. This alignment data may be analyzed by the alignment device or another electronic device (such as an application executed on the other electronic device and/or a remotely located computer). Then, based at least in part on the analysis, the alignment device may selectively provide the alignment feedback to the individual (e.g., when misalignment is detected or determined).
    Type: Application
    Filed: September 10, 2022
    Publication date: March 23, 2023
    Applicant: Dill-Davidson Innovations, LLC
    Inventors: Lisa Davidson, Scott Davidson, Dylan Davidson, Shmuel Silverman
  • Patent number: 9205157
    Abstract: The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. Melanoma).
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: December 8, 2015
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul Chapman, Lisa Davidson, José W. Saldanha
  • Publication number: 20120276046
    Abstract: The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. melanoma).
    Type: Application
    Filed: June 22, 2012
    Publication date: November 1, 2012
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Paul Chapman, Lisa Davidson, José W. Saldanha
  • Patent number: 8207308
    Abstract: The present invention is related to complementarity determining region (cdr)-grafted humanized r24 antibodies that bind to the gd3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine r24 antibody, and the humanized antibodies are useful in treating cancer (e.g. Melanoma).
    Type: Grant
    Filed: August 16, 2009
    Date of Patent: June 26, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul Chapman, Lisa Davidson, José W. Saldanha
  • Publication number: 20100008853
    Abstract: The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. melanoma).
    Type: Application
    Filed: August 16, 2009
    Publication date: January 14, 2010
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Paul Chapman, Lisa Davidson, Jose W. Saldanha